☰

Sheng Guo, Ph.D. - Publications

Affiliations: 
University of Pennsylvania, Philadelphia, PA, United States 
Tree Info Similar researchers PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Chen X, Xue J, Li Q, Guo S. Abstract 5963: NGS-based murine pan-cancer gene expression panel for immuno-oncology and tumor microenvironment studies Cancer Research. 80: 5963-5963. DOI: 10.1158/1538-7445.Am2020-5963  0.411
2020 Mao B, Ouyang D, Li H, Guo S. Abstract 3228: An online tool to balance baseline covariates for mouse clinical trials Cancer Research. 80: 3228-3228. DOI: 10.1158/1538-7445.Am2020-3228  0.312
2020 Xu X, Qian W, Guo S, Li HQ. Abstract 180: Systematic genomic analysis of matched PDX, PDX-derived organoids (PDXO), and PDX-derived cell lines (PDXC) Cancer Research. 80: 180-180. DOI: 10.1158/1538-7445.Am2020-180  0.409
2019 Zhang C, Jiang X, Guo S, Li Q. Abstract 4613: Mathematical modeling of tumor growth in mouse models Cancer Research. 79: 4613-4613. DOI: 10.1158/1538-7445.Am2019-4613  0.342
2019 Wang JJ, Mao B, Guo S, Ouyang DX, Li HQ. Abstract 4610: Prognostic impact of KRAS driver mutations and GSTT1 expression in colorectal cancer to FOLFOX treatment Cancer Research. 79: 4610-4610. DOI: 10.1158/1538-7445.Am2019-4610  0.399
2019 Chen X, Qian W, Guo S, Li H. Abstract 3418: A NGS-based SNP array for the identification of human xenograft tumors, mouse homograft tumors, human and mouse cell lines, organoids Cancer Research. 79: 3418-3418. DOI: 10.1158/1538-7445.Am2019-3418  0.354
2019 jiang x, li h, guo s. Abstract C118: Transcriptome comparison of orthotopic and subcutaneous patient-derived xenografts Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C118  0.398
2019 Xue J, Li HQ, Guo S. Abstract A026: An automated biomarker discovery platform based on in vitro pharmacology raw data Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A026  0.354
2019 Mao B, Guo S, Chen BX, Ouyang DX, Li H. Abstract A025: Comparative analysis of proteomic/transcriptomic profiles of a panel of GC-PDXs Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A025  0.358
2018 Zhu H, Wang C, Wang J, Chen D, Deng J, Deng J, Fan J, Badakhshi H, Huang X, Zhang L, Cai J, Guo S, Qian W, Nie Y, Li Q, et al. A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification. Journal of Thoracic Disease. 10: 5328-5338. PMID 30416780 DOI: 10.21037/Jtd.2018.09.18  0.322
2018 Cai J, Qian W, Fan B, Chen X, Guo S, Ouyang D, Yang W, An A, Bi J, Mo D, Li H. Abstract 5116: Development of murine tumor homograft panels and their genetic fingerprints for their identification to ensure the quality controlled I/O studies using these models Cancer Research. 78: 5116-5116. DOI: 10.1158/1538-7445.Am2018-5116  0.375
2018 Wang JJ, Zheng M, Huang X, Song Y, Qian W, Zhang L, Cai J, Guo S, Li HQ, Ouyang DX. Abstract 2167: Efficacy assessment of BTK inhibitor ibrutinib in de novo and viral-induced B cell lymphoma Cancer Research. 78: 2167-2167. DOI: 10.1158/1538-7445.Am2018-2167  0.332
2018 Mao B, Guo S, Li H, Wang X, Pan Y. Abstract 1283: Integrative genome-scale analysis of TCGA dataset for features of tumor immunity Cancer Research. 78: 1283-1283. DOI: 10.1158/1538-7445.Am2018-1283  0.406
2018 Xue J, Qian W, Guo S, An X, Ouyang X, Li HQ. Abstract 1016: Transcriptomic analysis of bulk tissues of large PDX collection as a novel platform discovering new TME target/drug Cancer Research. 78: 1016-1016. DOI: 10.1158/1538-7445.Am2018-1016  0.416
2018 Xue J, Qian W, Guo S, Cai J, Ouyang X, Li HQ. Abstract B209: Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B209  0.397
2018 Jin Y, Zhang L, Mao B, Zhai G, Li Z, Qiao M, An X, Zhang J, Guo S, Shi Q, Yang W. Abstract B014: MuScreen allows profiling of antitumor efficacy and biomarker readouts of drug candidates using well-characterized syngeneic models Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B014  0.378
2018 Mao B, Qian W, Guo S, Yang M, Cai J, Li HQ. Abstract A026: Analysis of cetuximab responses in PDX cohorts of different carcinomas Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A026  0.39
2018 Cai J, Ouyang X, Guo S, Zhang L, Wang J, Qian W, Xue J, Fan B, Thatte J, Kumari R, Li HQ. Abstract A013: In-depth annotations of the world's largest patient tumor-derived xenogragft (PDX) library for cancer research and preclinical pharmacology evaluation Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A013  0.428
2017 Hong B, Yang Y, Guo S, Duoerkun S, Deng X, Chen D, Yu S, Qian W, Li Q, Li Q, Gong K, Zhang N. Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. Oncotarget. PMID 28548943 DOI: 10.18632/Oncotarget.17765  0.316
2017 Xing F, Qian W, Dong C, Xu X, Guo S, Shi Q. Abstract 5597: Genomic profiling of syngeneic mouse cell lines andin vitroscreen of the models against checkpoint inhibitors and target agents for preclinical application Cancer Research. 77: 5597-5597. DOI: 10.1158/1538-7445.Am2017-5597  0.405
2017 Guo S, Mao B, Li HQ. Abstract 4534: Theory and methodology for the design and analysis of PDX mouse clinical trials Cancer Research. 77: 4534-4534. DOI: 10.1158/1538-7445.Am2017-4534  0.374
2017 Xue J, Qian W, Guo S, Cai J, Li HQ. Abstract 396: Detecting copy number variations using WES datasets in patient derived xenografts Cancer Research. 77: 396-396. DOI: 10.1158/1538-7445.Am2017-396  0.385
2016 Guo S, Chen D, Huang X, Cai J, Wery JP, Li QX. Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. Oncotarget. PMID 27409671 DOI: 10.18632/Oncotarget.10499  0.323
2016 Guo S, Qian W, Cai J, Zhang L, Wery JP, Li Q. Molecular pathology of patient tumors, patient derived xenografts and cancer cell lines. Cancer Research. PMID 27325646 DOI: 10.1158/0008-5472.Can-15-3245  0.371
2016 Zhang L, Zhang J, Guo S, Qian W, Wang Z, Shi Q. Abstract 5177: RNAseq and FACS profiling of syngeneic mouse models treated with immune checkpoint inhibitors enable biomarker discovery and model selection for cancer immunotherapy Cancer Research. 76: 5177-5177. DOI: 10.1158/1538-7445.Am2016-5177  0.393
2016 Zhang J, Guo S, Wang Z, Li z, Qiao M, Shi Q. Abstract 5176: Orthotopic syngeneic tumor models for preclinical evaluation of cancer immunotherapy strategies Cancer Research. 76: 5176-5176. DOI: 10.1158/1538-7445.Am2016-5176  0.346
2015 Chen D, Huang X, Cai J, Guo S, Qian W, Wery JP, Li QX. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. Oncotarget. PMID 26512781 DOI: 10.18632/Oncotarget.5886  0.348
2015 Mirarab S, Nguyen N, Guo S, Wang LS, Kim J, Warnow T. PASTA: Ultra-Large Multiple Sequence Alignment for Nucleotide and Amino-Acid Sequences. Journal of Computational Biology : a Journal of Computational Molecular Cell Biology. 22: 377-86. PMID 25549288 DOI: 10.1089/Cmb.2014.0156  0.524
2015 Li H, Wang Z, Guo S, Huang X, Wery J. Lessons from conducting mouse clinical trial (MCT) on a cohort of NSCLC patient derived xenografts (PDXs). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E18505  0.319
2015 Li H, Zhang lH, Yang J, Deng J, Guo S, Wang X, Huang X, Wery J, Ji J. Response to cetuximab by ESCC PDXs directly correlate to EGFR overexpression. Journal of Clinical Oncology. 33: e15078-e15078. DOI: 10.1200/Jco.2015.33.15_Suppl.E15078  0.345
2015 Wu R, Guo S, Cai J, Huang X, Yang J, Wery J, Li HQ. Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts Blood. 126: 2759-2759. DOI: 10.1182/Blood.V126.23.2759.2759  0.333
2015 Yang M, Cai J, Guo S, Wery J, Li HQ. Abstract 3581: Rapid conversion to resistance, of a colon PDX with ret-fusion, by ponatinib treatment could potentially be attributed to the introduction of the gate keeper mutation V804M Cancer Research. 75: 3581-3581. DOI: 10.1158/1538-7445.Am2015-3581  0.332
2015 Guo S, Qian W, Cai J, Wery J, Li HQ. Abstract 1926: Patient-derived xenografts seem to have closer global expression profile to that of the patient tumors of the corresponding cancer types, than the equivalent cell lines do Cancer Research. 75: 1926-1926. DOI: 10.1158/1538-7445.Am2015-1926  0.399
2015 Cai J, Chen D, Kumari R, Guo S, Yang J, Yang M, McKenzie A, Wang Z, Huang X, An X, Liu J, Wery J, Li H. Abstract 1472: Building comprehensive and fully annotated patient tumor derived xenogragft (PDX) library mirroring cancer patient population Cancer Research. 75: 1472-1472. DOI: 10.1158/1538-7445.Am2015-1472  0.39
2015 Deng J, Wang Z, Cai J, Guo S, Wery J, Li H. Abstract C82: Induction of resistances to crizotinib in lung patient derived xenograft Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C82  0.357
2015 Guo S, Qian W, Cai J, Zhang L, Wery J, Li H. Abstract B101: Molecular pathology of patient derived xenografts Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B101  0.402
2014 Li H, Yang J, Chen D, Yang M, Guo S, Huang X, Jiang J, Wang Z, Deng J, Wery J. Evaluation of the commonly used chemotherapeutics in the clinic by mouse clinical trial (MCT). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15009  0.321
2014 Guo S, Wang Z, Chen D, Yang J, Yang M, Huang X, Wery J, Li H. Abstract 1206: Parameters influencing the design of mouse clinical trial (HuTrialTM) Cancer Research. 74: 1206-1206. DOI: 10.1158/1538-7445.Am2014-1206  0.382
2013 Li H, Chen D, Guo S, Cai J, Chen Y, Wery J. Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts. Journal of Clinical Oncology. 31: 3544-3544. DOI: 10.1200/Jco.2013.31.15_Suppl.3544  0.329
2013 Zhang J, Guo S, Cai J, Sun Y, Mao G, Wang Z, Zhang L, Jin Y, Shi Q, Chen T. Abstract 1568: Evaluate the efficacy of new therapeutics using advanced metastatic mouse models. Cancer Research. 73: 1568-1568. DOI: 10.1158/1538-7445.Am2013-1568  0.415
2013 Yang M, Cai J, Guo S, Huang X, Yang J, Song X, Chen D, Zhang L, Jiang J, Wery J, Li H. Abstract C14: Squamous non-small cell lung cancer (NSCLC-SCC) patient-derived xenografts (PDX) from Asian patients have high response rate (RR) to cetuximab than those of adenocarcinoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C14  0.371
2013 Guo S, Li J, Zhang J, Qian W, Shi Q. Abstract B9: Tumor growth rate analysis enables cost efficient design of preclinical pharmacology studies. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B9  0.364
2013 Yang M, Cai J, Guo S, Yu S, Qian W, Song X, Wang Y, Wery J, Li H. Abstract A91: Activating EGFR mutation, G719A, was selected in the c-MET amplified NSCLC-PDX-LU1901 during the treatments by c-MET inhibitors and the resistance development. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A91  0.324
2013 Jiang J, Wang DD, Yang M, Chen D, Guo S, Cai J, Li L, Wery J, Lin PP, Li H. Abstract A157: Metastatic PDX modeling displays correlation between CTC and metastatic potential, both inhibited by chemotherapy. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A157  0.373
2010 Guo S, Kim J. Dissecting the molecular mechanism of drosophila odorant receptors through activity modeling and comparative analysis. Proteins. 78: 381-99. PMID 19714770 DOI: 10.1002/Prot.22556  0.534
2007 Guo S, Kim J. Molecular evolution of Drosophila odorant receptor genes. Molecular Biology and Evolution. 24: 1198-207. PMID 17331958 DOI: 10.1093/Molbev/Msm038  0.531
Show low-probability matches.